• June 21, 2012
  • Penn Researcher Recognized For Work in Developing Anxiety Disorder Medications


Karl Rickels, MD, Stuart and Emily B.H. Mudd professor of Human Behavior and professor of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, has received the 2012 "CINP Pioneers in Psychopharmacology Award" from the International College of Neuropsychopharmacology (CINP). Established in 2002 and given every two years, the awards honor three individuals worldwide who have made major contributions to the field.

Rickels, one of the Founding Members of the CINP in 1958, received the award for his groundbreaking work in the development of medications to treat anxiety disorders. Supported continuously by National Institute of Mental Health (NIMH) grants from 1959 to 2010, Rickels has contributed significantly to the development of anti-anxiety medications introduced into medicine since 1955. One of those grants was funded for 32 consecutive years an NIMH record.

Rickels is co-director of the Mood and Anxiety Disorders Treatment and Research Program, Department of Psychiatry, Perelman School of Medicine, and a Charter and Life Fellow of the American College of Neuropsychopharmacology (ACNP). Rickels has written or edited ten books and authored or co-authored more than 590 peer-reviewed publications, book chapters, and reviews.

Rickels has served on advisory committees for the Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH), including chairing the FDA-OTC Review Committee on over-the-counter daytime and nighttime sedatives and stimulants.

Rickels was recognized with a plaque at the CINP's 28th bi-annual meeting in Stockholm, Sweden in June. Also receiving the award this year are William Bunney, USA and Moussa B.H. Youdim, Israel. For a list of past winners, visit the CINP online.


Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.



Print, Share, or Save
Media Contact

Greg Richter

Other Contacts
Latest News
All News Releases

About Penn Medicine   Contact Us   Site Map   Privacy Statement   Legal Disclaimer   Terms of Use

Penn Medicine, Philadelphia, PA 800-789-PENN © 2015, The Trustees of the University of Pennsylvania